US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, one method led to much more weight loss.

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

Big drugmakers are abusing the drug patent process to generate extra revenue at the cost of patients, according to a new ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.